SCHEMBL13432

SCHEMBL13432

O[C@H]1CCCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27881191 1.00 SLC6A1 (0.46)
SCHEMBL10884 1.00
SCHEMBL11114 1.00
SCHEMBL5959172 1.00 SLC6A1 (0.46)
Hydrochloric Acid SCHEMBL311314 0.97
Methane SCHEMBL1492450 0.97
Ammonia Solution, Strong SCHEMBL27842570 0.97
Hydrochloric Acid SCHEMBL16718 0.97
Hydrochloric Acid SCHEMBL2351518 0.97
Hydrochloric Acid SCHEMBL916269 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3536780-B1 PROLINE HYDROXYLASE AND APPLICATION THEREOF ASYMCHEM LAB TIANJIN CO LTD (CN) 2025-05-14 EP claimed
CN-108017572-B Process for the preparation of (S) -3-hydroxypiperidines 江苏尚莱特医药化工材料有限公司 2023-10-17 CN claimed
CN-110759853-B Preparation method of (S) -N-BOC-3-hydroxy piperidine 上海科利生物医药有限公司 2023-06-13 CN claimed
CN-110759853-A Preparation method of (S) -N-BOC-3-hydroxypiperidine 上海科利生物医药有限公司 2020-02-07 CN claimed
CN-105439939-B A kind of synthetic method of (S)-N-Boc-3- hydroxy piperidine 四川恒康科技发展有限公司 2018-12-04 CN claimed
CN-105801518-B A kind of synthetic method of (S) -1-Boc-3- hydroxy piperidine 重庆博腾制药科技股份有限公司 2018-11-27 CN claimed
CN-105801518-A (S)-1-Boc-3-hydroxypiperidine synthesis method 重庆博腾制药科技股份有限公司 2016-07-27 CN claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
US-12637454-B2 Heterocyclic monoacylglycerol lipase (MAGL) inhibitors HOFFMANN-LA ROCHE INC. (US) 2026-05-26 US disclosed
EP-4743456-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2026-05-20 EP disclosed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment Neophore Limited (GB) 2026-02-17 US disclosed
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
EP-0497303-A2 Carbamic acid derivatives and method for preparing the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 EP disclosed
EP-0494816-A1 1,4-Dihydropyridine derivatives, process for their preparation and therapeutical composition containing them LABORATOIRE L. LAFON (FR) 1992-07-15 EP disclosed
US-5084392-A Ester interchange reaction for hydroxy lactones CHISSO CORPORATION (JP) 1992-01-28 US disclosed
EP-0441852-A1 MUSCARINIC RECEPTOR ANTAGONISTS. PFIZER LTD (GB) 1991-08-21 EP disclosed
EP-0439779-A2 Process for producing optically active hydroxy lactones CHISSO CORPORATION (JP) 1991-08-07 EP disclosed
EP-0376358-A1 Muscarinic receptor antagonists PFIZER INC. (US) 1990-07-04 EP disclosed
WO-1990005133-A1 MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1990-05-17 WO disclosed